About
AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar therapeutic botulinum toxin intended to provide a lower-cost alternative to Botox for treating neuromuscular conditions.
Explore AEON Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.